The directive for the Department of Health and Human Services to develop and test new models aimed at lowering drug costs ...

Medicare drug plans can now cover Eli Lilly & Co.’s obesity drug Zepbound as a treatment for obstructive sleep apnea, news that’s expected to prove a big boost for the drug company.

Shelby Knowles / Bloomberg via Getty Images Eli Lilly's Zepbound can be covered by Medicare Part D plans after the FDA approved the drug as a treatment for sleep apnea last month. Weight loss ...

The FDA approved Zepbound (tirzepatide) as the first prescription medication specifically for adults with moderate-to-severe obstructive sleep apnea (OSA) and obesity. People taking Zepbound lost ...

The popular weight-loss drugs were added to Medicare’s list of prices negotiated directly between the government and drug ...

Announcing the 15 medicines chosen for the second round of negotiations is one of the Biden administration’s final health ...

Announcement of the 15 medicines chosen for the second round of negotiations is one of the Biden administration’s final ...

But, no matter what direction the general market takes, some stocks could stand out, potentially in 2025, and most ...

Eli Lilly trims Q4 guidance but maintains optimism with promising drugs like Zepbound for sleep apnea and global launches ...

The Obesity Care Advocacy Network (OCAN), and more than 70 other patient advocacy organizations across the spectrum of related obesity co-morbidities, issued a statement urging the Trump ...

Cancer treatment access differs significantly between traditional Medicare and Medicare Advantage (MA), according to new research from the University of Colorado Cancer Center. The study ...

Sleep apnea is a serious sleep disorder that can have significant impacts on your overall health and quality of life. Characterised by repeated interruptions in breathing during sleep, this ...